A radiogenomics application for prognostic profiling of endometrial cancer.
Erling A HoivikErlend HodnelandJulie Andrea DybvikKari S Wagner-LarsenKristine E FasmerHege F BergMari K HalleIngfrid Salvesen HaldorsenCamilla KrakstadPublished in: Communications biology (2021)
Prognostication is critical for accurate diagnosis and tailored treatment in endometrial cancer (EC). We employed radiogenomics to integrate preoperative magnetic resonance imaging (MRI, n = 487 patients) with histologic-, transcriptomic- and molecular biomarkers (n = 550 patients) aiming to identify aggressive tumor features in a study including 866 EC patients. Whole-volume tumor radiomic profiling from manually (radiologists) segmented tumors (n = 138 patients) yielded clusters identifying patients with high-risk histological features and poor survival. Radiomic profiling by a fully automated machine learning (ML)-based tumor segmentation algorithm (n = 336 patients) reproduced the same radiomic prognostic groups. From these radiomic risk-groups, an 11-gene high-risk signature was defined, and its prognostic role was reproduced in orthologous validation cohorts (n = 554 patients) and aligned with The Cancer Genome Atlas (TCGA) molecular class with poor survival (copy-number-high/p53-altered). We conclude that MRI-based integrated radiogenomics profiling provides refined tumor characterization that may aid in prognostication and guide future treatment strategies in EC.
Keyphrases
- end stage renal disease
- magnetic resonance imaging
- machine learning
- ejection fraction
- newly diagnosed
- chronic kidney disease
- endometrial cancer
- copy number
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- contrast enhanced
- mass spectrometry
- patients undergoing
- artificial intelligence
- dna methylation
- young adults
- single molecule
- papillary thyroid
- diffusion weighted imaging